Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples
Launched by UNIVERSITEIT ANTWERPEN · Sep 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The COMBISCREEN project is a clinical trial aimed at developing a new test that can help screen for cervical cancer using self-collected samples. This means women can provide samples themselves, making the process easier and less invasive. The goal is to identify women who may have serious cervical conditions that require treatment, helping to catch issues early when they are most treatable.
To participate in this study, women must be between 25 and 64 years old and have been diagnosed with a significant cervical condition, such as cervical cancer or pre-cancer that needs treatment. It's important that they have not started any cancer treatment before joining the study. Participants will be asked to provide a sample and will receive information about what to expect throughout the trial. If you or someone you know meets these criteria and is interested, it's a great opportunity to contribute to important research in cervical health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female
- • 25 until 64 years old
- • Diagnosed with cervical cancer (CIN3+, irrespective of stage) OR in need of conization (irrespective of diagnostic or therapeutic purposes)
- • Has not started any form of cancer treatment prior to study enrollment
- • Written informed consent must be obtained from patient
- • Is able to understand the information brochure and what the study is about
- Exclusion Criteria:
- • Women that underwent hysterectomy
- • Pregnant women or 6 weeks post-partum
- • Treatment for cervical (pre)cancer in the last 6 months before participation in the study
- • Participating in another interventional clinical study (where e.g., a medical device, drug, or vaccine is evaluated) at the same time of participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.
- • Unable to give informed consent
- • Patient has severe anaemia
- • Patient received blood transfusion two weeks before sample collection
- • Blood sampling would compromise patients' overall health
- • Patients who are positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C.
- • Patients who are alcoholic or drug abusers
- • Patients with a history or current evidence of any condition or abnormality that might confound the results of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator.
About Universiteit Antwerpen
The University of Antwerp is a leading research institution based in Belgium, renowned for its commitment to advancing knowledge and innovation in various scientific fields. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials that aim to improve healthcare outcomes and enhance understanding of complex medical conditions. The University of Antwerp's dedicated research teams leverage cutting-edge methodologies and state-of-the-art facilities to conduct rigorous studies, ensuring adherence to the highest ethical standards and regulatory requirements. Through its clinical trial initiatives, the university strives to translate research findings into practical applications that benefit patients and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edegem, Antwerpen, Belgium
Patients applied
Trial Officials
Wiebren Tjalma, MD, PhD
Principal Investigator
Universiteit Antwerpen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported